Sugi Predict

Sugi Predict / Compounds / SCHEMBL10653331

SCHEMBL10653331

SCHEMBL10653331

C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 7/20 0.57
▸ REN P00797 4/20 0.57
▸ KDM4E B2RXH2 1/20 0.57
▸ F2 P00734 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ LTA4H P09960 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ PEPD P12955 1/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ PTGS1 P23219 1/20 0.57
▸ HTR2A P28223 1/20 0.57
▸ PTGS2 P35354 1/20 0.57
▸ HRH1 P35367 1/20 0.57
▸ THPO P40225 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ ACE2 Q9BYF1 1/20 0.57
▸ DPP4 P27487 3/20 0.53
▸ FAP Q12884 2/20 0.53
▸ DPP7 Q9UHL4 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401996 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL10658601 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL10829256 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL31401997 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL30139015 1.00 ACE (0.57) ACERENKDM4EF2LMNA
SCHEMBL593691 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL8316371 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115246 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL9164453 0.94 ACE (0.64) ACERENKDM4EF2LMNA
SCHEMBL2115244 0.94 ACE (0.64) ACERENKDM4EF2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374112-A1 Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof BDC CAPITAL INC. (CA) 2023-11-23 — — US claimed
CN-115181173-A Preparation method of Tirzepatide 深圳市健元医药科技有限公司 2022-10-14 — — CN claimed
WO-2022067445-A1 BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF CORPORATION GENACOL CANADA INC. (CA) 2022-04-07 — — WO claimed
JP-61053298-A — — None — — JP disclosed
US-12622975-B2 Peptide-conjugated prodrugs BRANDEIS UNIVERSITY (US) 2026-05-12 — — US disclosed
WO-2025264809-A1 CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF NEUROCRINE BIOSCIENCES, INC. (US) 2025-12-26 — — WO disclosed
WO-2025264785-A1 CHEMICALLY MODIFIED PEPTIDES AND USE THEREOF NEUROCRINE BIOSCIENCES, INC. (US) 2025-12-26 — — WO disclosed
US-20240287150-A1 METHODS AND COMPOSITIONS RELATING TO TISSUE-PROTECTIVE ERYTHROPOIETIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-08-29 — — US disclosed
US-20230374112-A1 Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof BDC CAPITAL INC. (CA) 2023-11-23 — — US disclosed
WO-2022272026-A1 METHODS AND COMPOSITIONS RELATING TO TISSUE-PROTECTIVE ERYTHROPOIETIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-12-29 — — WO disclosed
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-12-08 — — US disclosed
WO-2022067445-A1 BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF CORPORATION GENACOL CANADA INC. (CA) 2022-04-07 — — WO disclosed
US-20220098261-A1 METHODS AND COMPOSITIONS RELATING TO IMPROVED FORMS OF TARGETED ERYTHROPOIETIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-03-31 — — US disclosed
US-4719200-A Amino acid derivatives and antihypertensive drugs containing the same AJINOMOTO CO., INC. (JP) 1988-01-12 — — US disclosed
US-4590178-A DIURETICS AJINOMOTO COMPANY, INCORPORATED (JP) 1986-05-20 — — US disclosed
JP-S6153298-A AMINO ACID DERIVATIVE AND HYPOTENSOR CONTAINING SAME AJINOMOTO CO INC 1986-03-17 — — JP disclosed
EP-0173510-A2 Tripeptide derivatives for use as anti-hypertensive agents AJINOMOTO CO., INC. (JP) 1986-03-05 — — EP disclosed
EP-0155165-A2 Process for introducing phosphinoyl groups into amino groups AJINOMOTO CO., INC. (JP) 1985-09-18 — — EP disclosed
US-4536395-A DIPEPTIDES AJINOMOTO CO., INC. (JP) 1985-08-20 — — US disclosed
US-4472381-A Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them AJINOMOTO COMPANY INCORPORATED (JP) 1984-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622975-B2 Peptide-conjugated prodrugs PEPD, PAM, VIP ACE 1190/4885REN 2773/4885KDM4E 1136/4885
US-20220387610-A1 PEPTIDE-CONJUGATED PRODRUGS VIP, DNPEP, PEPD ACE 486/4885REN 3056/4885KDM4E 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.